SCRI Development Innovations, LLC

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Trial of Poor Performance Status Patients (ToPPS)

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Bevacizumab
Drug: Carboplatin

First Posted Date: 2009-05-04

Last Posted Date: 2015-05-15

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 172

Registration Number: NCT00892710

Locations: 🇺🇸
Aventura Medical Center, Aventura, Florida, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Memorial Regional Cancer Center, Hollywood, Florida, United States

and more 24 locations

Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Sunitinib

First Posted Date: 2009-04-24

Last Posted Date: 2016-09-07

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 54

Registration Number: NCT00887575

Locations: 🇺🇸
Holy Cross Hospital, Ft. Lauderdale, Florida, United States
🇺🇸
Florida Cancer Specialists North, Ft. Myers, Florida, United States
🇺🇸
National Capital Clinical Research Consortium, Bethesda, Maryland, United States

and more 11 locations

Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting

Completed

Conditions: Gastrointestinal Stromal Tumors

First Posted Date: 2009-04-07

Last Posted Date: 2010-08-04

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 200

Registration Number: NCT00877045

Locations: 🇺🇸
Georgia Cancer Specialists, Atlanta, Georgia, United States
🇺🇸
Virginia Cancer Institute, Richmond, Virginia, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States

and more 2 locations

Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma

Completed

Conditions: Renal Cell Carcinoma

First Posted Date: 2009-04-06

Last Posted Date: 2013-11-14

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 47

Registration Number: NCT00876382

Locations: 🇺🇸
Medical Oncology Associates of Augusta, Augusta, Georgia, United States
🇺🇸
St. Louis Cancer Care, Chesterfield, Missouri, United States
🇺🇸
Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States

and more 5 locations

Review of Molecular Profiling-Real Time Polymerase Chain Reaction (Rt-Pcr) in Unknown Primary Cancer

Completed

Conditions: Unknown Primary Cancer

First Posted Date: 2009-04-06

Last Posted Date: 2013-12-04

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 30

Registration Number: NCT00876408

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer

Completed

Conditions: Metastatic Breast Cancer

First Posted Date: 2009-04-06

Last Posted Date: 2011-11-21

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 198

Registration Number: NCT00876070

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸
Georgia Cancer Specialists, Atlanta, Georgia, United States

Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Ixabepilone
Drug: Cyclophosphamide

First Posted Date: 2009-03-23

Last Posted Date: 2021-11-22

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 168

Registration Number: NCT00866905

Locations: 🇺🇸
St. Louis Cancer Care, Chesterfield, Missouri, United States
🇺🇸
South Carolina Oncology Associates, PA, Columbia, South Carolina, United States
🇺🇸
Aventura Medical Center, Aventura, Florida, United States

and more 17 locations

Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas

Phase 2

Completed

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: Lenalidomide
Drug: Gemcitabine

First Posted Date: 2009-02-05

Last Posted Date: 2013-03-13

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 72

Registration Number: NCT00837031

Locations: 🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States

and more 6 locations

Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Sorafenib
Drug: Ixabepilone

First Posted Date: 2009-01-21

Last Posted Date: 2014-12-22

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 83

Registration Number: NCT00825734

Locations: 🇺🇸
Hematology Oncology Clinic, LLP, Baton Rouge, Louisiana, United States
🇺🇸
Florida Cancer Specialists, Ft. Myers, Florida, United States
🇺🇸
St. Louis Cancer Care, Chesterfield, Missouri, United States

and more 12 locations

Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Ixabepilone
Drug: Trastuzumab
Drug: Carboplatin

First Posted Date: 2009-01-14

Last Posted Date: 2014-12-22

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 60

Registration Number: NCT00821886

Locations: 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Medical Oncology Associates of Augusta, Augusta, Georgia, United States
🇺🇸
Mercy Hospital, Portland, Maine, United States

and more 9 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy